NOVEL CDK2 MECHANISM CONTROLS CELL PROLIFERATION

新型 CDK2 机制控制细胞增殖

基本信息

  • 批准号:
    6419217
  • 负责人:
  • 金额:
    $ 25.81万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2002
  • 资助国家:
    美国
  • 起止时间:
    2002-02-07 至 2005-12-31
  • 项目状态:
    已结题

项目摘要

Nontransformed T cells require IL-2 for proliferation, and IL-2Ralpha is an obligatory component of the high affinity biologically relevant IL-2R. Numerous studies have characterized the transcriptional up-regulation of IL-2Ralpha in mitogenically stimulated T cells. On the other hand, and of potential biological importance, post transcriptional control of IL-2Ralpha expression has yet to be adequately explored or definitively demonstrated. Data presented in this proposal clearly show that IL-2Ralpha expression is regulated at the translational level in primary T cells exposed to mitogenic stimuli. We show that increased translation of the IL-2Ralpha transcript is paralleled by the induction of IL-2 signaling pathways, and we suggest that translational up-regulation of IL-2Ralpha requires the activity of the cell cycle regulatory kinase, cdk2. Interestingly, we found that cdk2 expression was also controlled at a post- transcriptional level and, most likely, by a cdk2-dependent mechanism. These studies identify novel actions of cdk2 and suggest that previously unrecognized mechanisms contribute to the expression of IL-2Ralpha and cdk2. We also present data showing that cdk2 activation and IL-2 signaling are interdependent processes in splenic T cells. We suggest that cdk2 activity is required for the efficient translation of IL-2R and that signals generated by the IL-2R facilitate cdk2 activation by maintaining the down-regulation of the cdk2 inhibitor, P27kip1. These interactions and the involvement of cdk2 in the translation of two important cell cycle regulatory molecules - IL-2Ralpha and cdk2 itself - form the focus of our proposal. Specifically, we will examine potential mechanisms by which cdk2 activity might control the translation of IL-2Ralpha in primary splenocytes. We will identify the region of the 5' untranslated region of the IL-2Ralpha mRNA that is responsible for translational regulation and will determine if proteins bind to this region in a manner dependent on cdk2 activity. We will also determine if cdk2 activity modulates the synthesis or the stability of cdk2. Additional experiments will assess the contribution of IL-2 signaling to the continued down-regulation of p27kip1 in TCR-activated splenocytes. Lastly, the mechanism by which TCR activation promotes the expression of cyclin A will be delineated.
非转化的T细胞需要IL-2进行增殖,而IL-2 R α是高亲和力生物学相关IL-2 R的必需组分。 许多研究已经表征了促有丝分裂刺激的T细胞中IL-2 R α的转录上调。 另一方面,具有潜在生物学重要性的是,IL-2 R α表达的转录后控制尚未得到充分探索或明确证明。 该提案中提供的数据清楚地表明,在暴露于促有丝分裂刺激的原代T细胞中,IL-2 R α表达在翻译水平上受到调节。 我们表明,增加翻译的IL-2 R α转录是通过诱导IL-2信号通路,我们认为,翻译上调IL-2 R α需要的细胞周期调节激酶,cdk 2的活性。 有趣的是,我们发现cdk 2的表达也在转录后水平上受到控制,并且很可能是通过cdk 2依赖性机制。 这些研究确定了cdk 2的新作用,并表明以前未被识别的机制有助于IL-2 R α和cdk 2的表达。 我们还提出的数据表明,cdk 2激活和IL-2信号是相互依赖的过程中脾T细胞。 我们认为,cdk 2的活性是必需的IL-2 R的有效翻译和IL-2 R产生的信号促进cdk 2激活通过维持下调的cdk 2抑制剂,P27 kip 1。 这些相互作用和cdk 2参与两个重要的细胞周期调节分子- IL-2 R α和cdk 2本身-的翻译形成了我们的建议的重点。具体而言,我们将研究cdk 2活性可能控制原代脾细胞中IL-2 R α翻译的潜在机制。 我们将鉴定负责翻译调控的IL-2 R α mRNA的5'非翻译区,并确定蛋白质是否以依赖于cdk 2活性的方式与该区域结合。 我们还将确定cdk 2活性是否调节cdk 2的合成或稳定性。 另外的实验将评估IL-2信号传导对TCR活化的脾细胞中p27 kip 1持续下调的贡献。 最后,TCR活化促进细胞周期蛋白A表达的机制将被描述。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Warren Jackson Pledger其他文献

Warren Jackson Pledger的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Warren Jackson Pledger', 18)}}的其他基金

Molecular Biology of Lung Cancer among Puerto Ricans
波多黎各人肺癌的分子生物学
  • 批准号:
    8551283
  • 财政年份:
    2013
  • 资助金额:
    $ 25.81万
  • 项目类别:
Molecular Biology of Lung Cancer among Puerto Ricans
波多黎各人肺癌的分子生物学
  • 批准号:
    8464841
  • 财政年份:
    2012
  • 资助金额:
    $ 25.81万
  • 项目类别:
Ponce School of Medicine - Moffitt Cancer Center Partnership
庞塞医学院 - 莫菲特癌症中心合作伙伴关系
  • 批准号:
    7938255
  • 财政年份:
    2009
  • 资助金额:
    $ 25.81万
  • 项目类别:
Ponce School of Medicine - Moffitt Cancer Center Partnership
庞塞医学院 - 莫菲特癌症中心合作伙伴关系
  • 批准号:
    7938265
  • 财政年份:
    2009
  • 资助金额:
    $ 25.81万
  • 项目类别:
Ponce School of Medicine - Moffitt Cancer Center Partner
庞塞医学院 - 莫菲特癌症中心合作伙伴
  • 批准号:
    7291528
  • 财政年份:
    2006
  • 资助金额:
    $ 25.81万
  • 项目类别:
Ponce School of Medicine - Moffitt Cancer Center Partnership
庞塞医学院 - 莫菲特癌症中心合作伙伴关系
  • 批准号:
    8325737
  • 财政年份:
    2006
  • 资助金额:
    $ 25.81万
  • 项目类别:
Planning and Evaluation Core External
规划和评估核心外部
  • 批准号:
    7556038
  • 财政年份:
    2006
  • 资助金额:
    $ 25.81万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    7246295
  • 财政年份:
    2006
  • 资助金额:
    $ 25.81万
  • 项目类别:
Planning and Evaluation Core- Internal
规划和评估核心-内部
  • 批准号:
    7246297
  • 财政年份:
    2006
  • 资助金额:
    $ 25.81万
  • 项目类别:
Ponce School of Medicine - Moffitt Cancer Center Partnership
庞塞医学院 - 莫菲特癌症中心合作伙伴关系
  • 批准号:
    7496437
  • 财政年份:
    2006
  • 资助金额:
    $ 25.81万
  • 项目类别:

相似海外基金

Modulation of T lymphocyte Activation by ß2-Adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
  • 批准号:
    RGPIN-2019-06980
  • 财政年份:
    2022
  • 资助金额:
    $ 25.81万
  • 项目类别:
    Discovery Grants Program - Individual
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
用于基于细胞毒性 T 淋巴细胞的癌症免疫疗法的精准肿瘤新抗原识别流程
  • 批准号:
    10581488
  • 财政年份:
    2022
  • 资助金额:
    $ 25.81万
  • 项目类别:
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
  • 批准号:
    574979-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 25.81万
  • 项目类别:
    University Undergraduate Student Research Awards
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
用于基于细胞毒性 T 淋巴细胞的癌症免疫疗法的精准肿瘤新抗原识别流程
  • 批准号:
    10332251
  • 财政年份:
    2022
  • 资助金额:
    $ 25.81万
  • 项目类别:
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
  • 批准号:
    574984-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 25.81万
  • 项目类别:
    University Undergraduate Student Research Awards
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
  • 批准号:
    574985-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 25.81万
  • 项目类别:
    University Undergraduate Student Research Awards
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
  • 批准号:
    574978-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 25.81万
  • 项目类别:
    University Undergraduate Student Research Awards
Investigating the cell-based activity of a new class of cytotoxic T-lymphocyte antigen-4 (CTLA-4) small molecule inhibitors
研究一类新型细胞毒性 T 淋巴细胞抗原 4 (CTLA-4) 小分子抑制剂的细胞活性
  • 批准号:
    444149
  • 财政年份:
    2021
  • 资助金额:
    $ 25.81万
  • 项目类别:
    Operating Grants
Novel pathways in T lymphocyte differentiation and function
T 淋巴细胞分化和功能的新途径
  • 批准号:
    RGPIN-2015-05491
  • 财政年份:
    2021
  • 资助金额:
    $ 25.81万
  • 项目类别:
    Discovery Grants Program - Individual
Modulation of T lymphocyte Activation by ß2-Adrenergic Receptor Signalling Pathways
通过 α2-肾上腺素能受体信号通路调节 T 淋巴细胞激活
  • 批准号:
    RGPIN-2019-06980
  • 财政年份:
    2021
  • 资助金额:
    $ 25.81万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了